Regulation & Compliance

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

A jury verdict against Olin Corporation in a contract dispute with Shintech will cost the chemical giant $185 million and raises industry-wide questions.

The Midwest bank saw record earnings and shareholder returns in 2025, but a rise in nonperforming loans adds a layer of complexity to its growth story.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

With federal Grad PLUS loans ending July 2026, a Massachusetts agency is expanding its programs to prevent a major funding crisis for students.

As digitalization untethers companies, a fierce new competition among nations has begun. Who will win the battle for talent, capital, and the future?

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

A nonprofit's Super Bowl ad with Mike Tyson declared war on processed food. Who's behind the campaign, and can it change how America eats?

Foreclosure filings jumped 32% from a year ago, with some states seeing alarming rates. Is this a market correction or a sign of a looming crisis?

Forget chatbots. Stardock's new app gives you persistent AI 'staff' on your PC that learn your workflow, promising a new era of private productivity.

For the eighth straight year, Tavant earns HousingWire's Tech100 award. We explore how its AI is setting a new standard for the entire housing industry.

As retirees seek safety from market swings, annuities are booming. But do these complex products deliver on their promises of secure, lifelong income?

With its first dedicated private credit fund, Brigade Capital is targeting a complex, underserved market segment to deliver what larger lenders often miss.

Amid rising enforcement, RegTech firm Change Agents adds top compliance experts to guide firms through a complex digital finance and sanctions landscape.

As NewLake Capital Partners prepares its 2025 earnings call, investors are watching. The report is a crucial test for the cannabis REIT and the sector.

A new security tool aims to expose the invisible risks of identity sprawl in GitHub, promising real-time visibility where traditional tools fall short.

After 8 years in stealth, an AI lending platform from Wall Street veterans is out. It promises to cut losses by 50% and level the field for local banks.

A new partnership embeds microchips into drug vials, aiming to revolutionize DSCSA compliance and create a tamper-proof pharmaceutical supply chain.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

With nearly half of U.S. adults facing high blood pressure, a new alliance is launching 'Hypertension Bites' to make control achievable. But can it work?